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Abstract: The novel SARS-CoV-2 is responsible for causing the ongoing outbreak of coronavirus disease
19 (COVID-19), a systemic infection in humans. Ever since it was first detected in December 2019, the
number of confirmed cases has continued to increase. Within a short period, this disease has become a
global issue, and therefore it is characterized as a pandemic. The current understanding and explanations
are based on epidemiological, clinical and physiological observations. Besides, it remains a great challenge,
as much remains to be understood about this new disease-causing virus. Therefore, we seek to provide
an overview of SARS-CoV-2, including its classification, origin, genomic structure, replication cycle,
transmission, pathogenesis, clinical aspects, diagnosis, treatments, prevention and vaccine options. We
conducted a literature search for the articles published up to August 2020 using the keywords ‘SARCoV-2’ and ‘COVID19’ in medical databases; PubMed, google scholar, EMBASE, and web of science.
Based on the information collected, the emerging COVID-19, caused by SARS-CoV-2, exhibits strong
infectivity but less virulence in terms of severity of disease and mortality rates in certain age groups. It
inflicts more damage in terms of peoples’ health and well-being, social life, and global economic impacts.
Unfortunately, there is no adequate global and standard response to this pandemic to date, and each
country is facing a crisis based on its situation, expertise, and hypotheses. While there is no effective
therapy and vaccine against the novel SARS-CoV-2 yet, preventive measures are the only tool available to
our disposal to control the spread of the COVID-19 pandemic. Ongoing and future research is focused
more on developing standard treatment strategies, and efficacious vaccines, which would be useful to
tackle this pandemic globally.
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Introduction
Over the past couple of decades, three major international
outbreaks of coronaviruses (CoVs) have occurred causing
considerable global health concern. The first human CoV
outbreak occurred in late 2002. Because the symptoms
associated with this CoV outbreak was characterized by
severe acute respiratory syndrome (SARS) and the genomic
sequence of the causative virus differed significantly from
other CoVs previously known to cause human disease, the
causative virus was named SARS-CoV (1). A decade later
in 2012–2013, another respiratory disease; Middle East
Respiratory Syndrome (MERS) broke out and the causative
agent of this respiratory disease was named Middle East
respiratory syndrome coronavirus (MERS-CoV). Most
recently in December 2019, a group of patients presented
with pneumonia-like symptoms (2,3). Most of these
people had a high fever and some had dyspnea, with chest
radiographs revealing invasive lesions in both lungs (4,5).
Since the etiology of this pneumonia was unknown, the
authorities started conducting an epidemiologic and etiologic
investigation. In January 2020, analyses from the lower
respiratory tract samples by culture, direct PCR, and wholegenome sequencing identified a novel CoV (2019-nCoV),
the causative agent for the observed pneumonia cluster (6).
WHO renamed the disease as COVID-19 while the
causative agents were named as SARS-CoV-2. The number
of positive COVID-19 cases is increasing worldwide (7) and
to date, it has now been confirmed on six continents and in
more than 100 countries. Being a novel CoV, information is
just beginning to emerge regarding biochemical properties,
molecular etiology, and clinical aspects of the virus.
Indeed, many issues about COVID-19 still remain
unresolved as the current immunological concepts are
insufficient to explain the causes for different clinical
phenotypes, incubation periods among individuals, cytokine
storm with lymphopenia and the damage to organ cells.
Accordingly, the current understanding and explanations
about COVID-19 are based on epidemiological, clinical
and physiological observations (8). Epidemiological
observations are supported by the hypothesis of virus
transmission from person-to-person within a distance of
2 m from an infected person. However, high aerosol and
surface stability of SARS-CoV-2 whereby, the virus remains
viable and infectious in aerosol for hours, and the airborne
transmission can occur besides close-distance contacts (9).
On the other hand, early clinical evidence suggests that
severe cases of COVID-19 are frequently characterized by
hyper inflammation, renin-angiotensin-aldosterone system
© Annals of Translational Medicine. All rights reserved.

imbalance, vasculopathy thrombine microangiopathy and
intravascular coagulopathy (10). Meanwhile, other studies
have identified D-dimer (11), prothrombin time (12)
and thrombocytopenia (13) as prognostic markers for
severe COVID-19. In terms of physiological observations,
COVID-19 affects multiple organ systems particularly the
respiratory system with some patients rapidly progressing
to acute respiratory distress syndrome (ARDS) (14).
Similarly, cardiac injury is also a common complication
in severe COVID-19. As a result of such complications,
severe COVID-19 patients are usually admitted to intensive
care units (ICUs) and are likely to die. The elderly and
particularly those with comorbidities are at the greatest risk
of death particularly due to lung injury (14).
In this review, we aim to update the current knowledge
about SARS-CoV-2, including its classification, origin,
genomic structure, replication cycle, transmission,
pathogenesis, clinical symptoms, diagnosis, and available
treatment options. We present the following article in
accordance with the Narrative Review reporting checklist
(available at http://dx.doi.org/10.21037/atm-20-5272).
Methods
We conducted a comprehensive literature search for the
articles published up to August 2020, using keywords ‘SARCoV-2’ and ‘COVID19’ in medical databases; PubMed
(https://www.ncbi.nlm.nih.gov/pubmed), a search engine
accessing the MEDLINE database of references and
abstracts on biomedical topics and life sciences. We also
searched coronavirus-related literature using EMBASE,
google scholar, and web of science. Study selection was
based on three medical databases; Web of Science PubMed,
and EMBASE. Based on the keywords mention above,
qualitative and quantitative data were extracted through
the interpretation of published articles. Eligibility criteria
included articles indexed in PubMed. Exclusion criteria
were non-peer reviewed or unpublished reports. English
language restriction was also applied. No clinical trials and/
or guidelines were included in the review. Overall, a total
of 26,611 articles were retrieved, out of which 130 were
selected and used in this review.
Discussion
Coronaviruses
Coronaviruses belong to subfamily orthocoronovirinae of
the family Coronaviridae and order Nidovirales. Based on
Ann Transl Med 2020;8(24):1686 | http://dx.doi.org/10.21037/atm-20-5272
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Figure 1 Schematic representation of the type of Coronaviruses. HCoVs belong to either the Alphacoronaviruses or Betacoronaviruses.
HCoV229E, human coronavirus 229E, HCoVOC43, human coronavirus OC43; HCoVNL63, human coronavirus NL63; HCoVHKU1,
human coronavirus HKU1; SARS-COV, severe acute respiratory syndrome coronavirus; MERS-CoV, Middle East respiratory syndromerelated coronavirus; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

the phylogenetic analysis, the Coronavirinae subfamily is
classified into four groups, namely; Alphacoronaviruses
(α-CoVs), Betacoronaviruses (β-CoVs), Gammacoronaviruses
(γ-CoVs), and Deltacoronaviruses (δ-CoVs) (15). Studies
have revealed that γ-CoVs and δ-CoVs usually infect birds
and possibly mammals (16). However, they are never known
to cause illness in humans. On the contrary, α-CoVs and
β-CoVs are known to infect mammals and are capable
of causing illnesses to humans (17). Human coronavirus
(HCoV) was isolated for the first time in the year 1965 from
the nasal discharge of patients with the common cold (18).
Reports based on the phylogenetic tree analysis revealed
that there are seven known strains of HCoVs. These include
HCoV-229E (229E), HCoV-OC43 (OC43), HCoV-NL63
(NL63), HCoV-HKU1 (HKU1), severe acute respiratory
syndrome coronavirus (SARS-CoV), Middle East respiratory
syndrome coronavirus (MERS-CoV), and the recently
identified SARS-CoV-2 (19). The analysis further suggested
that the viral strain; 229E, and NL63 belong to the α-CoVs
while OC43, HKU1, SARS-CoV, MERS-CoV, and SARSCoV-2 belong to the β-CoVs (20) (Figure 1). These suggest
that HCoVs belong to either the alpha or beta coronavirus
genera. Based on the evidence, viral strains; 229E, OC43,
NL63, and HKU1 are already adapted to humans and widely
circulated among the human population (21). Therefore,
these viruses have been identified to infect humans although
with low pathogenicity and mild respiratory syndrome (22).
Coronavirus strains; 229E, OC43, and NL63 are distributed
globally and cause 15–29% of all common colds (23).
Although, SARS-CoV, MERS-CoV, and SARS-CoV-2
were likely acquired by zoonotic transmission through an
intermediate host species (20). SARS-CoV-2, unlike SARS-

© Annals of Translational Medicine. All rights reserved.

CoV and MERS-CoV, may be an adapted virus to human
species for the reason that, there are many asymptomatic
carriers and its fatality is mainly observed in older patients
with comorbidities (6,24-26).
Origin of coronavirus and SAR-CoV-2
The SARS-CoV and MERS-CoV are known to have
originated from bats, which are their natural reservoirs, and
then transmitted to humans through an intermediate host;
civets, and dromedary camels, respectively (27). Based on
some evidence, various proposals have been made regarding
the origin of SARS-CoV-2 (28). Anderson KG et.al
proposed that the origin may have been from (I) natural
selection of the virus in a natural host/intermediate reservoir
before zoonotic transfer to humans (II) natural selection
of the virus in humans following the zoonotic transfer and
(III) adaptation of the virus during the passage in culture/
animal model. The first case scenario purports that SARSCoV-2 originated from bats as the natural host; however, it
must have been transmitted to humans via an intermediate
host in the Huanan seafood market (29-33). To date, SARSCoV has been isolated from other animals including the
pangolins. Phylogenetic sequence analysis of the virus
from pangolins revealed 91% sequence similarity to SARSCoV-2, which infects humans suggesting that SARS-CoV-2
originated in bats as the natural reservoirs and transmitted
to humans through pangolins as the intermediate hosts
(Figure 2) (34,35). However, it is worth noting that the
Huanan market was not trading in bats but other animals
including a hedgehog, badger, snake, pangolin, and bird.
Thus, the direct transmission of SARS-CoV-2 from bats
to humans appears to be highly unlikely (27). The second
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Figure 2 Schematic representation of the zoonotic transmission of SARS-CoV-2: the novel SARS-CoV-2 is believed to have originated
from bats, then passed through an intermediate host possibly pangolin, to an individual (across the species barrier into humans) which then
resulted in the human to human transmission within populations. SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

case scenario suggests that the progenitor of SARS-CoV-2
was selected and became adapted to the human host after
acquiring the genomic features during asymptomatic
human-to-human transmission. However, it would not
be wise to rule out the third case scenario involving the
selection of the virus during the passage in the culture/
animal model. Since the research involving CoVs has been
performed for many years using the in vitro/or animal
models in biosafety level 2 laboratories, SARS-CoV-2
probably may have acquired adaptation mutations during
the passage in cell culture/animal model. Nevertheless, indepth studies to elucidate the actual origin of SARS-CoV-2
are important in order to take precautionary measures
against similar future outbreaks.
Genomic organization of SAR-CoV-2
The SARS-CoV-2 is a spherical, enveloped, and positivesense RNA virus (Figure 3A). The complete genome size
of SARS-CoV-2, WuhanHu1 strain is 29.9 kb (36). Studies
have shown that CoV genomes contain a variable number
of open reading frames (ORFs) (Figure 3B) (37). The first
ORF (ORF-1a and ORF-1b) accounts for two-thirds of the
viral RNA genome and encodes two polyproteins namely,
pp1a and pp1ab and 16 non-structural proteins (NSP).
The remaining ORFs encode accessory and structural
proteins including four essential proteins, namely, the spike
(S) glycoprotein, small envelope (E) protein, matrix (M)
protein, and nucleocapsid (N) protein (17). The S protein,
a heavily glycosylated protein forms homotrimeric spikes
on the viral surface that mediates viral entry into host cells

© Annals of Translational Medicine. All rights reserved.

(Figure 3). M protein, the most abundant protein along with
E protein gives the virus its shape. The main function of E
protein is to release the viral particles from host cells while
the N protein is required for the packaging of the viral
RNA into the viral particle during viral assembly.
Mutations and genetic recombination of coronaviruses
and SARS-CoV-2
Viruses, particularly RNA viruses are characterized by
a high rate of mutations. Recently, Pachetti et al. (38)
observed that some mutations were either close to or within
RNA -dependent RNA polymerase (RdRp) hydrophobic
cleft which is the target for several drug candidates in the
pipeline suggesting that such drugs would either fail in
preclinical/clinical studies or soon develop drug resistance
due to mutations. Similarly, Stefanelli et al. (39) compared
the full-length SARS-CoV-2 genome sequences isolated
from two patients, (I) a Chinese tourist who visited Italy
and (II) Italian patients, with other European sequences and
other places around the world. The phylogenetic analysis
suggest that multiple SARS-CoV-2 strains were introduced
to Europe or that the initial virus that was introduced to
Europe continue to evolve through mutations. Consistent
with these observations, partial sequence results of SARSCoV-2 obtained by the Uganda Virus Research Institute
(UVRI) in Entebbe, Uganda demonstrates that different
SARS-CoV-2 sequences from Ugandan patients’ cluster
with viral sequences from the origin where the patient
contracted the virus. Besides, another study has identified
116 important mutations out of which three mutations are
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A

B

Figure 3 Virion and genomic structure of SARS-CoV-2. (A) Schematic structure of the SARS-CoV-2 virion, (B) structural organization
of the SARS-CoV-2 genome. Structural proteins, Spike (S), envelope (E), membrane (M) and nucleocapsid (N) proteins, non-structural
proteins translated from ORF 1a and ORF 1b and accessory proteins, including 3a, 3b, 6, 7a, 7b, 8a, 8b, and 9b (for SARS-CoV), and 3a, 6,
7a, 7b, 8, and 10 (for SARS-CoV-2) are indicated. SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; ORF, open reading frame.

most common; 29095C>T in the N gene, 28144T>C in
ORF8 gene, and 8782C>T in ORF1ab gene (40). There
is a high possibility that these mutations might affect the
pathogenicity and spread of the SARS-CoV-2 (40).
CoVs have a moderate recombination frequency (41).
The recombination and the mutation favor them to adapt
to new hosts (42,43). Reports have started to emerge for
genomic recombination of HCoVs including; OC43,
HKU1, NL63, SARS-CoV (44), and MERS-CoV. Studies
have shown that HCoVs; OC43 has A to E five distinct
genotypes. Genotype A is exemplified by the prototype
VR759 strain that was isolated in 1967 (45). Studies have
further shown that genotype D has emerged because of the
recombination between naturally occurring genotypes B and
C viruses. Moreover, genotype E was also known to have
emerged from genotype B, C, and D viruses recombination
at different breakpoints in the genes compared to the
generation of genotype D (46). The other HCoVs strain;
NL63 has the possibility for genetic recombination,
for example, the Amsterdam 1 and 496 strains have
recombination breakpoints site in S gene (47). HKU1 strain
was also reported of having recombinant forms between
genotype B and C in some nonstructural proteins and
haemagglutinin esterase genes (43). A history of possible
recombination with lineages of alpha- and gamma-CoVs
has been reported for SAR-CoVs (48). A large number

© Annals of Translational Medicine. All rights reserved.

of the recombinant region and many specific breakpoints
had been identified especially in the RdRp gene (48).
Other studies have demonstrated that the MERS-CoV had
recombination events between the different lineages (49).
It caused human infections in Riyadh, Saudi Arabia as well
as an outbreak in South Korea in 2015 (49,50). Therefore,
the foregoing paragraph reveals that genetic recombination
events in CoVs results in the emergence of novel viruses
with unique genetic diversity and possibly unpredictable
virulence following transmission to humans. As the multiple
recombinant strains of CoVs are circulating among
different animal species, it is just a matter of time until the
emergence of new recombinant CoVs and cause another
outbreak.
SARS-CoV-2 and its replicative cycle
The CoVs are thought to enter cells via two distinct
pathways, namely, one mediated by type II, transmembrane
protease, serine 2 (TMPRSS2) present at the cell surface
and the other mediated by cathepsin L in the endosomes.
Angiotensin-converting enzyme 2 (ACE-2) which is found
in cells of the lower respiratory tract of humans is the
cellular receptor for SARS-CoVs (51). SARS-CoV-2 also
utilizes ACE-2 as a receptor to gain entry into the target
cells (52). The viral spike (S) glycoprotein of the SARSCoV-2 envelope surface attaches to ACE-2 of the target
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cells to initiate viral entry. Bertram et al. (53) analyzed the
role of type II transmembrane serine proteases (TTSPs),
human airway trypsin-like protease (HAT) and TMPRSS2
in SARS CoV2 activation and found that HAT cleaves
and activates the viral (S) glycoprotein in order to initiate
viral entry and it is coexpressed with the viral receptor,
ACE-2 in bronchial epithelial cells and pneumocytes. As
determined by mutagenesis and mass spectrometry analyses,
HAT cleaved the (S) glycoprotein at R667 for cell-cell
fusion while TMPRSS2 cleaved the (S) glycoprotein at
multiple sites. The observation that TMPRSS2 activates
the (S) glycoprotein for viral entry were also confirmed
by other authors (54-56). The binding of S glycoprotein
of SARS-CoV-2 and ACE-2 receptor is the most critical
step for the entry of the virus to the target cells. One
study demonstrated that human cells expressing ACE-2
enhanced the entry of SARS-CoV-2 (57). The S protein
comprises two functional subunits; S1 subunits and S2
Subunits. S1 subunit binds to the host cell receptor while
the S2 subunit is responsible for the fusion of the viral and
cellular membranes. Studies have revealed that the distal S1
subunit comprises the receptor-binding domain (RBD) that
contributes to the stabilization of the prefusion state of the
membrane-anchored S2 subunit that contains the fusion
machinery (58). Nevertheless, different CoVs use distinct
domains within the S1 subunit to recognize a variety of
attachment and entry receptors, SARS-CoV and several
SARS-related coronaviruses (SARSr-CoV) interact directly
with ACE-2 to enter target cells (31,59). S1 can be further
divided into a C-terminal domain (CTD) and an N-terminal
domain (NTD), both of which can function as a receptorbinding entity (60,61), whereas mouse hepatitis CoV
engages the receptor with its S1 NTD (62). In the case of
SARS-CoV-2, the region of the S protein that is responsible
for ACE-2 interaction has been identified as the S1 CTD
(SARS-CoV-2-CTD).
Upon the entry and uncoating of coronavirus into the
target cell, the positive sense genomic RNA is translated
from open reading frame 1a/b (ORF1a/b) generating the
replicase proteins. The replicase proteins use the genome
as a template to generate full-length negative-sense RNAs,
which then serve as templates in generating additional fulllength genomes. CoV mRNAs contain a common 5’ leader
sequence fused to downstream gene sequences. The RNA’RNA polymerase recognizes the 3’ end of the positive
strand and full-length template and further proceed to
synthesize positive-sense RNA. It continues to synthesize
until it encounters the transcriptional regulatory sequences
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(TRS) located between the coding regions. The translation
of sub-genomic mRNAs leads to the production of
structural and non-structural viral proteins. Once sufficient
structural proteins and genomic viral RNA are formed,
viral RNA is then assembled with viral structural proteins
into virions (Figure 4). Viral assembly and budding then
occur via the smooth-walled vesicles in the endoplasmic
reticulum-Golgi intermediate compartment (ERGIC) (63).
Through evolution, most viruses are unable to replicate on
their own but relay on the host cell’s machinery for effective
replication. It is therefore, conceivable that adapted viruses
can easily replicate to produce intact virions whereas
non-adapted viruses cannot such that the products from
their replication process in the infected cells can induce
inflammation when released.
Transmission of SARS-CoV-2
The SARS-CoV-2 is transmitted from person-to-person
at close contact through droplets, aerosol, and possibly
through fecal-oral transmission. Liquid droplets/aerosol
particles exhaled from the infected person during speech
or sneezing can linger in the air (64). If it is inhaled by
an uninfected person, then inhaled aerosolized particles
can penetrate to the depths of the lungs and deposited
in the alveoli causing serious respiratory tract infection
(65,66). Indeed, data obtained from studies conducted in
Wuhan Hospital demonstrated the presence of SARSCoV-2 RNA in air samples collected in the Hospital and
also in the surroundings leading to the conclusion that the
airborne route should be considered a plausible pathway
for virus transmission (9). Furthermore, accumulating
evidence suggests that SARS-CoV-2, just like many of
its related viruses, may also be an enteric virus which can
be transmitted via the fecal-oral route (67,68). There are
reported cases of COVID-19 infection occurring during
pregnancy and the due concern for mother-to-fetal vertical
transmission. However, presently, there is little evidence
on vertical transmission of SARS-CoV-2, prevalence and
clinical features of COVID-19 during pregnancy, regardless
to say, infected mothers are at greater risk for more severe
respiratory complications from COVID-19 infection (69).
Nevertheless, it should be noted that an infected mother is
capable of transmitting SARS-CoV-2 through respiratory
droplets during breastfeeding. A study conducted to
investigate the stability of SARS-CoV-2 through five
different environmental conditions (aerosols, stainless steel,
plastic, copper, and cardboard) (70) showed that SARSCoV-2 remained viable for 3hrs and infectious viral titers
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Figure 4 The life cycle of coronavirus in host cells; the virion lifecycle begins when the spike (S) protein binds to ACE2, the cellular
receptor. Then the virus releases its plus sense genomic RNA into the host cell. The minus strand is then formed from the plus strand
genomic RNA, from which subgenomic mRNAs are formed by transcription and then translated into relevant viral proteins. Genome
RNA and viral protein are assembled and then released out of the cell. SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; ER,
endoplasmic recticulum; ACE2 receptor, angiotensin-converting enzyme 2 receptor.

decrease gradually after 3hrs (70). It further suggested that
SARS-CoV-2 was more stable on stainless steel and plastic
than on cardboard and copper and the viable virus could be
detected on these surfaces even after 72 h (70). Therefore,
SARS-CoV-2 can also be contracted by an uninfected
person through touching contaminated surfaces or objects
and then touching the face. The COVID-19 patients who
are asymptomatic or at the incubation period can even shed
and transmit the virus to other persons (71).
Pathogenesis of SARS-CoV and SARS-CoV-2 infection
The mechanisms of pathogenicity of SARS-CoV-2 are
not fully understood. However, several studies have been
done on SARS-CoV and it’s believed that SARS-CoV-2
mechanisms of disease causation are somewhat similar
to that of SARS-CoV. In the case of SARS-CoV-infected
patients, high virus titers (25), elevated macrophage,
monocyte, and neutrophil infiltration in the lung (72),
and increased proinflammatory chemokines and cytokines
in the serum (73) causes extensive lung damage. This
indicates that the viral-induced cytopathic effect and/
or immunopathology induced by hyper-cytokinemia are
responsible for the clinical deterioration of SARS-CoV

© Annals of Translational Medicine. All rights reserved.

infection. Cytokine/chemokine profile analysis showed
that the level of cytokines, including CXCL-10, tumor
necrosis factor α (TNF-α), interleukin-6 (IL-6), and IL-8
are high that results to the poor prognosis in SARS-CoV
infections (74). The level of proinflammatory cytokines
in the serum (Interferon γ [IFN-γ], transforming growth
factor-β, IL-1, IL-6, and IL-12) and chemokines (CXCL9,
CXCL10, CCL2, and IL-8) were found to be high in
patients with the severe disease when compared to patients
with uncomplicated SARS (73,75-77). Besides, immunopathological processes involved in lung injury during
SARS-CoV infection are thought to result from the early
induction of IL-2, and CXCL10 as well as the subsequent
hyperproduction of pro-inflammatory cytokine IL-6
with a coinciding lack of anti-inflammatory cytokine IL10 production (76). Furthermore, robust and persistent
expression of IFN-α, -γ and IFN-stimulated genes (ISGs)
accompanied early SARS sequelae (78). Other studies have
demonstrated that SARS-CoV infections result in a delayed
expression of type I IFN (79). The delay in type I IFN
signaling, accompanied by robust virus replication, has been
demonstrated to promote the accumulation of pathogenic
inflammatory monocyte/macrophages, which resulted in
elevated lung cytokine/chemokine levels, vascular leakage,
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and impaired virus-specific T cell responses (80). However,
particularly in COVID-19 patients, initial plasma IL-1Rα,
IL-1β, IL-7, IL-8, IL-9, IL-10, basic GCSF, GMCSF, FGF,
IFNγ, IP-10, MCP-1, MIP-1α, MIP-1β, TNF-α, PDGF,
and vascular endothelial growth factor concentrations
were higher in COVID-19 patients as compared to healthy
controls. On the other hand, Zou et al. (81) evaluated the
correlation between coagulation functions and COVID-19
status and found that coagulation dysfunction was common
in patients with COVID-19. In particular, they observed
that there was fibrinogen and D-dimer elevations, and
the degree of elevation was related to the severity of
the COVID-19 disease. However, as patients recovered
from severe disease, fibrinogen and activated partial
thromboplastin time also returned to normal. These results
suggest that immunopathology also plays an important
role in the development of disease severity. It is however,
worth noting that the presumed immunopathogenesis of
COVID-19 are better explained according to the clinical
and pathological characteristics of the disease, as well as
the protein-homeostasis-system (PHS) hypothesis (8).
During the incubation period of COVID-19, substances
are produced by SARS-CoV-2 that can induce lung injury
as well as other organs such as the cardiac system, which
initiate the focus of disease. These substances that are
potentially toxic spread locally and systematically and
bind to receptors on target organ cells. Innate immune
cells and proteins likely control different sized substances
during the early stage of COVID-19 infection such
that clinical symptoms of the disease including fever,
myalgia and pneumonia begin to appear at this stage (8).
However, the cytokine storm in progressive severe disease
may occur as a result of excessive immune cell activation
against large amounts of substances that are produced at
this stage of the disease. The etiological substances that
induce inflammation, as well as various organ injuries are
the smaller substances derived from the virus infected
cells where the cytokine imbalance may be responsible for
target cell injury. Furthermore, substances emanating from
initial tissue injury, as well as secondary bacterial infection
can induce further inflammation when released locally or
systematically (8).
Antibody-dependent enhancement of CoVs infection
Some vaccine strategies induce neutralizing and protective
antibodies against the target S protein of SARSCoV. However, the main concern is that vaccinations
against different kinds of coronaviruses have different
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outcomes (82). Studies have shown that anti-spike antibodies
offer protection against transmissible gastroenteritis and
mouse hepatitis. However, this particular antibody boosts
feline-coronavirus (FCoV) infections (83). Moreover,
antibody-dependent enhancement (ADE) of virus infection
has been observed in viruses including yellow fever, dengue,
HIV, and FCoV (82). Even though the mechanism of ADE
is poorly understood, it is believed that the virus-specific
antibodies enhance the entry of the virus and replication
into macrophages/monocytes and granulocytes cells
through the interaction with complement/Fc receptors (82).
Using SARS-CoV clinical isolates and pseudotyped viruses,
Jaume et al. (84) demonstrated that SARS-CoV anti-spike
antibodies potentiate ADE infection of both monocytic
and lymphoid human immune cell lines. Similarly, Yip
et al. (85) suggested the occurrence of ADE in SARSCoV infected immune cell types, particularly monocytic
lineage. However, in addition to monocytes, the presence
of anti-viral antibodies enhanced the infection of human
macrophages. Nevertheless, macrophages did not support
productive viral replication or modify the expression of
some pro-inflammatory cytokines. These findings suggest
the occurrence of ADE infection of immune cells by SARSCoV, however, the outcomes of such an alternative infection
pathway on the cell functionality/homeostasis remain
unclear. The ADE is likely to complicate SARS-CoV-2
vaccine research and development efforts.
Clinical aspects of SARS-CoV-2
Clinical presentation of SARS-CoV-2 infection is similar to
those of SARS-CoV and MERS-CoV infections (Table 1).
Table 1 summarizes the disease-causing human CoVs and
their clinical symptom. The clinical symptom of COVID-19
usually appears 2 to 14 days after exposure. COVID-19
patients commonly experience fever, dry cough, shortness
of breath or difficulty breathing, and runny nose as the
symptoms. However, other common symptoms include
muscle pain, chills, headache, sore throat, loss of taste, or
smell (27). Furthermore, approximately 25% of COVID-19
patients experience diarrhea as is the case with SARSCoV and MERS-CoV infections (5). However, in severe
COVID-19 cases, symptoms include acute respiratory
distress syndrome, metabolic acidosis, septic shock, and
bleeding and coagulation dysfunctions. During the disease,
severe and critically sick patients may show moderate to
low fever. It’s however, worth noting that some COVID-19
patients may remain asymptomatic though capable of

Ann Transl Med 2020;8(24):1686 | http://dx.doi.org/10.21037/atm-20-5272

Annals of Translational Medicine, Vol 8, No 24 December 2020

Page 9 of 19

Table 1 Human coronavirus based on their types, clinical symptom and incubation time
HCoVs

Genus and lineage Symptom

229E

Alphacoronavirus

General malaise, nasal discharge, fever, sneezing, headache, 2–5 days approx. NA
sore throat and cough

OC43

Betacoronavirus,
lineage A

General malaise, fever, headache, sneezing, nasal discharge, 2–5 days approx.
sore throat, and cough

NL63

Alphacoronavirus

Rhinorrhea, cough, hypoxia, fever, tachypnea, obstructive
laryngitis

2–5 days approx.

HKU1

Betacoronavirus,
lineage A

Fever, cough, dyspnea, and running nose

2–5 days approx.

SARS-CoV

Betacoronavirus,
lineage B

Fever, myalgia, malaise, headache, chills, dyspnea,
nonproductive cough, respiratory distress, and diarrhea

2–11 days approx. SARS in 2002

MERS-CoV

Betacoronavirus,
lineage C

Cough, fever, sore throat, myalgia, chills, arthralgia, dyspnea, 2–13 days approx. MERS in late 2012
diarrhea, pneumonia, and vomiting

SARS-CoV-2 Betacoronavirus,
lineage B

Incubation time

International outbreak

Fever, cough, shortness of breath or difficulty breathing, chills, 2-14 days approx. COVID19 in late 2019
muscle pain, headache, loss of taste or smell, sore throat

HCoVs, human coronaviruses; 229E, human coronavirus 229E; OC43, human coronavirus OC43; NL63, human coronavirus NL63; HKU1,
human coronavirus HKU1; SARS-COV, severe acute respiratory syndrome coronavirus; MERS-CoV, Middle East respiratory syndromerelated coronavirus; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; COVID19, coronavirus disease 2019.

transmitting the virus. Initial reports of COVID-19
indicated infrequent occurrence of disease in children.
However, subsequently, multiple reports described children
affected by COVID-19 with varying degrees of severity
(86-88). Accordingly, during this COVID-19 pandemic,
cases of severe Kawasaki disease (KD)-like disease referred
to as Multisystem inflammatory syndrome in children
(MIS-C) have been reported in large cities in Western
countries. Children affected by MIS-C are usually older
and manifest shock syndrome with acute heart failure,
gastroenteric symptoms and other symptoms such as KD (8).
Based on currently available information from clinical
expertise personal, there are four higher risk groups
for COVID-19: (I) over-70s, regardless of any medical
conditions, (II) under 70s who have the underlying health
conditions like respiratory diseases (Asthma or chronic
obstructive pulmonary disease), diabetes, heart failure,
hepatitis, kidney disease, long term neurological problem,
and other spleen problem, (III) pregnant women (IV)
people with complex health problem like HIV/AIDS
patients, organ transplant patients and cancer patients with
active chemo/radiotherapy.
Just as much as there are differences in clinical
manifestations, there are also differing incubation periods
among the infected individuals. The observed differences in
incubation periods are likely due to different substances that
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are produced according to the infected cells such as the upper
respiratory epithelial cells or the lower respiratory endothelial
cells (8). Due to the differences in the intracellular
environments of the infected cells, the timing as well as the
duration of release of viruses and related substances can also
be different. Therefore, viruses and substances in the upper
respiratory epithelial cells may be easily discharged outside
the host whereas those in regional lymph nodes and lower
respiratory endothelial cells are discharged inside the host.
There is evidence to suggest that viruses become attenuated
and less virulent once passaged multiple times. It is therefore,
possible that people who become infected with SARS-CoV-2
after it has infected several individuals later in the pandemic
may be asymptomatic compared to those individuals infected
earlier in the pandemic. Similarly, herd immunity can also be
achieved as a result of cross-immunity from previous CoVs
infections such as those that cause common cold. At the
beginning of COVID-19 pandemic, the mortality rate was
higher among the elderly although this later varied among
populations. Currently, it is unknown if the age distribution
of all infected persons will change over time due to herd
immunity obtained from other CoVs infections.
Diagnosis of SARS-CoV-2 infection
The WHO recommends mass testing of all suspected cases,
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isolation, and treatment of all confirmed cases and tracing
of all contacts of confirmed cases. However, the high and
efficient rates of SARS-CoV-2 transmission among persons
have caused global health concern and have overwhelmed
healthcare systems of even the developed nations in Europe
and the United States of America. Although there are
much lower confirmed cases in Africa compared to the
developed nations, apparently due to low mass testing
capability, there is grave concern regarding how developing
countries of Africa and elsewhere will be able to cope with
the COVID-19 pandemic, given the limping state of the
healthcare systems in these countries. Consequently, as
a result of the above, most African countries were quick
to close off their borders to the outside world to curtail
imported cases of COVID-19 that would subsequently
result in local community transmission. Interestingly,
although the WHO had projected that Africa could
become the next epicenter of COVID-19 pandemic after
Europe, confirmed cases of COVID-19 in many African
countries including Uganda has been significantly low
even months following the first reported case. Many
African countries were reasonably prepared to handle the
COVID-19 outbreak given the lessons learned from the
previous handling of the Ebola and Marburg outbreaks
in the continent. Even though commercial diagnosis kits
for SARS-COV-2 are available, the antigen detection kits
preparation process is complicated and time-consuming
as it requires the preparation of monoclonal antibodies
and polyclonal antibodies. Therefore, detection of viral
RNA using RT-PCR (89) remains a gold standard and it is
currently the only diagnostic test approved and available
for SARS-CoV-2 infection. Although SARS-CoV-2 can be
detected in various human samples including respiratory
and fecal samples, testing has been validated for RT-PCR
primarily for nasal, nasopharyngeal and oropharyngeal
specimens. The rapid spread of SARS-CoV-2 infection in
the United States of America and around the world led to
Emergency Use Authorization (EUA) which facilitated the
development and availability of molecular diagnostic kits
without vigorous examination prior to the approval by the
Food and Drug Administration (FDA). To these effects,
the following RT-PCR platforms have been made available
for molecular diagnosis of SARS-CoV-2 infection, namely,
the Roche Cobas SARS-CoV-2, the Cepheid Xpert Xpress
SARS-CoV-2 and the Abbott ID Now COVID-19 assays.
The run time for each assay are 3.5 h, 45 min and 5 min,
respectively. Basu et al. (90), analyzed the performance of
these three test kits using nasopharyngeal swabs transported
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in viral transport media and dry nasal swabs. Basu et al. (90)
found out that regardless of the method of collection and
sample type, Abbott ID Now COVID-19 gave negative
results in a third of the samples that tested positive by
Cepheid Xpert Xpress. This observation underscores the
high level of unreliability associated with the molecular tests
currently in use for COVID-19 diagnosis.
On the other hand, Gao et al. (91) investigated the role
of clinical laboratory markers in the differential diagnosis
of the severe forms of COVID-19 using 43 adult patients.
The patients were classified into mild and severe groups. A
comparison of the hematological parameters between the
mild and the severe groups showed significant differences
in IL-6, D-dimer, glucose, thrombin time, fibrinogen and
C-reactive protein levels. In particular, high levels of IL-6
and D-dimer were closely related to occurrence of severe
COVID-19 in adult patients. Furthermore, the different
cardiac manifestations and the use of cardiac-specific
biomarkers in terms of their prognostic use in determining
the clinical outcomes and disease severity are reviewed in
Shafi et al. (92).
One of the challenges in the management of COVID-19
is the use of an accessible and reliable diagnostic modality
that can serve as an alternative to RT-PCR. To this effect,
recent studies have demonstrated the usefulness of Chest
computed tomography (CT) scan in the diagnosis of
COVID-19 (93-95). Indeed, in one instance, the use of
CT scan provided an accurate COVID-19 diagnosis even
when the molecular RT-PCR was negative (94). On the
other hand, in emergency situations, the imaging features
of routine admission chest X-ray in patients suspected for
COVID-19 infection can be employed for diagnosis. In
this case, Ippolito et al. (96) observed that overall, the Chest
X-ray sensitivity for SARS-CoV-2 pneumonia was 57% and
that sensitivity was higher when COVID-19 symptoms had
started more than five days before.
Update on the therapy of SARS-CoV-2 infection
Viral diseases such as COVID-19 are self-limiting whereby,
the host’s immune system can potentially control the
infection without complications. However, in the case of
COVID-19, a small proportion of patients experience
disease complications such as progressive pneumonia and
ARDS. Therefore, scientists are searching for treatment
modalities that can prevent disease progression and
complications. Current treatment modalities under
consideration include antivirals and antiviral-effecting
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drugs, as well as immunomodulators and supportive
treatment options.
Antivirals and antiviral-effecting drugs
Currently, there is a continuing search for the antiviral
drugs that are effective against the SARS-CoV-2 infection.
Patients infected with SARS-CoV-2 are required to be
kept in bed and closely monitored for vital signs and
levels of oxygen saturation (97). Being a novel virus, it will
conceivably take several years before effective novel antiviral
drugs can become available for COVID-19 treatment.
Considering the above challenges, the other solution is to
systematically screen existing drugs to determine whether
some drugs may have activity against SARS-CoV-2.
Accordingly, recent screening of existing drugs revealed
that an antiretroviral drug used in the treatment of human
immunodeficiency virus (HIV) infection, Kaletra, which
comprises of two protease inhibitors; ritonavir and lopinavir
may have therapeutic effects on SARS-CoV-2 (98-102).
Another study reported that chloroquine showed
inhibitory effects on SARS-CoV-2 in vitro (103) and an
early clinical trial showed that chloroquine had a significant
effect on clinical outcome and viral clearance (104).
As a result of these studies, COVID-19 patients with
moderate, and severe cases but without contraindications
to chloroquine were recommended to be treated with
500 mg of chloroquine twice a day (97). On the other hand,
hydroxychloroquine which is an analog of chloroquine with
better pharmacodynamics profiles compared to chloroquine
has been shown to have an anti-SARS-CoV-2 activity
in vitro (105). Because of having better pharmacodynamics
profiles than chloroquine, hydroxychloroquine allows the
use of higher daily dose and fewer concerns for drug-todrug interactions (106,107). Based on these observations,
Gautret et al. (108) tested the use of azithromycin and
hydroxychloroquine as a treatment for COVID-19 in
a non-randomized clinical trial. They reported that
hydroxychloroquine effectively cleared viral nasopharyngeal
carriage of SARS-CoV-2 in only 3 to 6 days (108). Although
small studies have shown a potential benefit of chloroquine/
hydroxychloroquine in combination with or without
azithromycin for the treatment of COVID-19. Saleh
et al. (109) investigated whether the use of these medications
alone or in combination can lead to a prolongation of
the Quality Time (QT) interval, possibly increasing the
risk of Torsade de pointes (TdP) and sudden cardiac
death. Paradoxically, in the largest reported cohort of
COVID-19 patients treated to date with chloroquine/
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hydroxychloroquine with or without azithromycin, no
instances of TdP or arrhythmogenic death was reported.
Similar observations were also made by other authors
(110,111), however, Sarayani et al. observed that though
treatment with azithromycin resulted in QT prolongation,
the use of chloroquine/hydroxychloroquine alone did
not produce these effects. In light of all these underlying
controversies, the WHO has had to suspend further clinical
trials involving the use of chloroquine/hydroxychloroquine
for the treatment of COVID-19.
Based on initial studies conducted in China using
remdesivir, a new antiviral drug that was originally
developed for the treatment of Ebola to treat COVID-19
patients (103), more clinical trials were subsequently
conducted in the United States. Indeed, most recently,
remdesivir has been approved by the Food and Drug
Administration of the United States for emergency
treatment of COVID-19 patients based on preliminary
results which demonstrated that remdesivir can significantly
reduce hospitalization days for severe COVID-19 patients
from 15 down to 11 days. Other antiviral drugs that have
been tested for COVID-19 treatment but with less success
include ribavirin, favipiravir and oseltamivir.
Immunomodulators
COVID-19 is known to induce the release of proinflammatory cytokines including IL-1β and IL-6, which
mediate lung injury as well as tissue inflammation, fever
and fibrosis. Indeed, high levels of IL-6 is the cause of the
cytokine storm and therefore, suppression of these proinflammatory cytokines may provide treatment options.
The immunomodulatory agents used in the treatment
of COVID-19 include; Tocilizumab, Interferons and
Corticosteroids. Tocilizumab is a recombinant humanized
anti-human IL-6 receptor monoclonal antibody that binds
to IL-6 receptor with high affinity. Although it is approved
for the treatment of cytokine release syndrome (CRS) and
rheumatoid arthritis, currently there is not enough data
to recommend its use for COVID-19 therapy. On the
other hand, interferons are a group of cytokines with nonspecific antiviral effects. In this case, interferon α and β
have been suggested as candidates for COVID-19 therapy.
Interferons act by binding to their receptors on the cell
surface membrane, which results in the phosphorylation of
STAT1. STAT1 then translocates in to the nucleus where
it activates the expression of the interferon-stimulated
genes (ISGs). Activated ISGs lead to immunomodulatory
effects which interfere with viral replication. However,
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currently, studies that may support the use of interferons
for COVID-19 therapy are inconclusive. Corticosteroids,
particularly, Methylprednisolone has been suggested as
an adjuvant for COVID-19 treatment. Corticosteroids
are widely used in the treatment of severe pneumonia and
lung injury because of their ability to suppress systemic
inflammation (8). Indeed, studies have shown that ARDS
patients treated with Methylprednisolone showed a rapid
resolution of pneumonia lesions and clinical improvement
and in fact early treatment using corticosteroids as soon as
possible may reduce the aberrant immune reactions in the
potential stages of ARDS (112,113).
General and supportive treatment
An alternative treatment option is the use of convalescent
serum or plasma from COVID-19 recovered patients (114).
Recovered patients would have developed specific antibody
responses which may help neutralize viruses in newly
infected individuals. This treatment approach was effectively
and successfully employed in the United States during the
2014/2015 Ebola outbreak (115,116). However, considering
the exponential increase in the number of new infections,
the use of convalescent sera may be of limited benefit in an
outbreak situation since newly infected patients exceed the
ability of previous patients to provide donor plasma.
Currently, more than 80 clinical trials are going on
for potential SARS-CoV-2 treatments (117). Meanwhile,
scientists continue searching for new drugs that would
combat multiple coronaviruses. For instance, the surface S
protein of the CoVs provides a tantalizing target. The Jiang
research group in China and other research groups around
the world have found antibodies and compounds binding to
the S protein (118), that could prevent CoVs from invading
human cells. It should, however, be noted that studies are
at an early stage and these compounds need to be verified,
developed into drugs, and tested in animals that could
take years. It is therefore, advisable that in the meantime,
early corticosteroid with preventive antibiotic treatment is
very inexpensive and can help to prevent from collapse of
medical system in developing countries.
Vaccine research and development efforts
There is an urgent necessity to produce and distribute
effective and safe vaccines to immunize a large number
of people all over the world from SARS-CoV-2. Owing
to the wide geographic diversity of the pandemic and
number of people who need the vaccine, more than one
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vaccine developmental approach is required. Therefore,
the collaborative efforts among the biotechnological
companies, industry, academicians, and government are
essential to design effective vaccine strategies (119,120).
For a vaccine to be widely accepted, a high degree of safety
is the most primary concern. There is also a theoretical
risk that vaccination could even worsen the case of SARSCoV-2 infection, as we have seen in the case of feline
coronaviruses and huge vaccine-challenge animal models
of SARS-CoV (119,121). Nonetheless, efficacy trials need
to be evaluated considering both benefit and harm. There
is also a possibility of controlled human challenge trials,
where a small number of young healthy volunteers could be
vaccinated and then exposed to SARS-CoV-2 (119). In this
trial, as there are no effective therapies for COVID-19 to
rescue volunteers if a complication develops, volunteers are
at risk of developing severe disease or even death. To nullify
these risk factors, the SARS-CoV-2 challenge strain that
causes mild illness will be utilized (119). Another concern
is that even if it is effective in young healthy adults, it does
not necessarily mean to be effective among older adults.
Therefore, careful evaluation is needed before conducting
the trials.
Considering some of the facts above, it is likely to take
time before a safe, effective, and affordable vaccine becomes
available. Nevertheless, most of the vaccine development
process is moving toward clinical evaluation. The replicating
and nonreplicating viral vectors, traditional recombinant
protein and subunit vaccines, and nucleic acid DNA and
mRNA approaches are some of the encouraging platforms
for vaccine development (119). However, each platform
has some advantages as well as demerits. Studies have
suggested that the major alterations in the spike protein are
not extensive. Therefore, traditional recombinant protein
technology can be used to express the spike protein (e.g.,
Sanofi, Novavax). However, protein vaccines will require
a potent adjuvant, but the availability of certain adjuvants
is a major concern. The recent progress made in mapping
out the SARS-CoV-2 spike protein will pave the way
towards the development of vaccines (82). Of particular
interest is the use of a relatively new vaccine strategy,
RNA vaccines that can elicit potent immune responses
against pathogens and certain cancers (122,123). Unlike
traditional vaccines that utilize purified proteins from the
pathogens, whole deactivated or live attenuated viruses,
the RNA-based vaccines use mRNA which upon entering
cells, are translated to immunogenic molecules that in
turn, stimulate the immune system. This process has been

Ann Transl Med 2020;8(24):1686 | http://dx.doi.org/10.21037/atm-20-5272

Annals of Translational Medicine, Vol 8, No 24 December 2020

used effectively against some cancers (124,125) and clinical
trials are underway for several other cancers (126). Besides,
the production of RNA-based vaccines is less expensive
and more rapid when compared to traditional vaccines.
Therefore, RNA-based vaccine has a major advantage in
pandemic situations. Clinical trials for an mRNA-based
SARS-CoV-2 vaccine have indeed begun in the United
States. Study subjects received the mRNA vaccine in two
doses, 28 days apart and the safety and immunogenicity are
still in the process to assess.
The other SARS-CoV-2 vaccine relies on producing
an immune response against the S protein to block its
docking and interaction with the host ACE-2 receptor (127).
Based on the recombinant expression of the S protein,
Novavax has also generated immunogenic virus-like
nanoparticles (128). The Clover Biopharmaceuticals on
the other hand is developing a trimerized SARS-CoV-2 S
protein as a subunit vaccine using their patented TrimerTag technology. Similarly, a consortium comprising of
Texas Children’s Hospital Center for Vaccine Development
and the University of Texas Medical Branch and New York
Blood Center has tested a subunit vaccine comprised of
only the receptor-binding domain (RBD) of the SARSCoV S protein (127,129,130). When administered with
alum as an adjuvant, it elicited protective immunity
following the homologous virus challenge. The advantage
of using an RBD-based vaccine is its ability to minimize
host immunopotentiation (127). A safe and effective
vaccine needs to be produced in billions of doses for the
entire world. Even though new technologies do have the
capacity to generate this, there is a need to set up a fund for
distributing to every individual’s level. Therefore, it is high
time the international agencies collaborated for this noble
cause.
Limitations
COVID-19 is wracking havoc globally irrespective of age,
gender, sex, ethnic background, lifestyle, and socioeconomic
status. Due to the high transmission rate of SARS-Cov-2,
it has been a challenge to contain the viral infection.
Moreover, the number of trained personnel and health care
professionals to conduct testing and taking care of infected
individuals has also been a big issue. Despite ongoing
research, the precise knowledge about the life cycle of
SARS-Cov-2 is very limited, a prerequisite to developing
highly specific and more effective therapeutics. Moreover,
the current understanding and explanations of this disease
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are based on epidemiological, clinical and physiological
observations (8). A large number of labs worldwide are
studying COVID-19, resulting in a huge number of
publications in recent months. However, humanity is still
waiting for effective anti-SARS-Cov-2 therapy.
Conclusions
The outbreak of COVID-19 rapidly swept across the
entire world in a matter of two to three months. As we
write this article COVID-19 continues to spread in
different parts and corners of the world, scientists have
made extraordinary progress in characterizing the novel
SARS-CoV-2 and are working incessantly to develop
novel therapies and vaccines against the virus. However,
many issues about COVID-19 still remain unresolved
as the current immunological concepts are insufficient
to explain the causes for different clinical phenotypes,
incubation periods among individuals, cytokine storm with
lymphopenia and the damage to organ cells. Accordingly,
the current understanding and explanations about
COVID-19 are based on epidemiological, clinical and
physiological observations as explained in the introduction
section. There is mounting evidence pointing to the fact
that there are multiple SARS-CoV-2 strains in global
circulation. Compared to SARS and MERS, the emerging
COVID-19, caused by SARS-CoV-2, exhibits strong
infectivity but less virulence in terms of severity of disease
and mortality rates in certain age groups. However,
given the rapid and efficient transmission rates of SARSCoV-2 it has caused in just a few weeks, the COVID-19
appears to inflict more damage in terms of peoples’ health
and well-being, social life, and global economic impacts.
While there is no effective therapy and vaccine against the
novel SARS-CoV-2 yet, preventive measures are the only
tool available to our disposal to control the spread of the
COVID-19 pandemic. To curtail the transmission, the
WHO recommends isolation of suspected cases, testing,
and treatment of confirmed cases and tracing of all contacts
and quarantining. However, at the individual level, people
are advised to avoid becoming infected by practicing social
distancing, staying at home, frequently washing hands
thoroughly with soap or using alcohol-based sanitizer,
avoiding touching of the face particularly the eyes, nose,
and mouth with unwashed hands among others. If all
these preventive interventions are carefully followed, there
is mounting evidence from countries across the world,
suggesting that these measures help curtail the epidemic.
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The recent emergence of COVID-19 pandemic along with
other high lethality emerging and re-emerging viruses such
as SARS-CoV, MERS-CoV, H5N1, H7N9, Ebola and
Marburg should serve as a strong reminder and wake up
call to scientists the world over, who should strive to reduce
the probability of their re-emergence and the emergence of
other novel viruses promptly. For instance, strengthening
the investigation of animal etiology, establishing stringent
procedures and containment of high-risk pathogens,
reducing direct contacts with wildlife while limiting the
massive destruction of their habitats, maintaining the
barriers between natural reservoirs and human society and
completely eradicating wildlife trading, preventing zoonotic
transmission will help to achieve these goals.
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